New rabies vaccine could reduce cost, risk

by April Reese Sorrow

(Medical Xpress)—Researchers at the University of Georgia used a common dog disease-canine parainfluenza-to build a new vaccine to protect humans and animals from the rabies virus. Developers hope the new treatment will reduce costs and increase accessibility to a vaccine for a disease that currently kills 55,000 people a year.

Current vaccines use weakened pathogens to develop resistance. UGA professor Biao He's technique is different. Using genetic engineering, he and his team of researchers inserted a non-viral piece of the into parainfluenza virus 5, called PIV5, which a virus that causes respiratory infection in dogs. Using PIV5 as a delivery mechanism to expose humans and other animals to important pathogens-rabies in this case-allows them to create antibodies that will protect against future infections.

"This could be man's new best friend in delivering vaccines," said He, who is a professor of infectious diseases in the UGA College of Veterinary Medicine and the study's lead author.

According to results recently published in the , the vaccine is effective in building immunity. The study tested the efficacy of the drug on a mouse model when administered orally, through the nose and into muscle. When the mice were administered a lethal dose of rabies, survival was 100 percent when they had received the vaccine nasally or into muscle. Survival was 50 percent when the vaccine was administered orally.

"This is first report of an orally effective candidate in animals based on PIV5 as a vector," said He, who also is a Georgia Research Alliance distinguished investigator and member of the Faculty of Infectious Diseases. "These results indicate this is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals, and PIV5 is a potential vector for oral vaccines."

In the U.S., rabies are seen most often in wild animal populations. The reports an average of two human deaths per year from rabies in the U.S.

While death rates in the U.S. are low, rabies is expensive to control. The CDC estimates the disease costs more than $300 million annually, costs that include the vaccination of companion animals, animal control programs, maintenance of rabies laboratories and medical costs. Humans at risk for contracting rabies, like those who work with wild , even if immunized need booster shots after the fact if a rabid animal bites them. Humans infected with rabies who have not been vaccinated pay high prices for medical treatment that is time consuming and painful.

He is hopeful the new vaccine will be more effective and will require less of the drug to create resistance, reducing the cost.

"The virus we are using as a vector has been used as a component for kennel cough vaccines, so we know how to mass-produce it. And, we also know that manufacturing it won't be a problem in terms of producing a large quantity at a cheaper price," He said. "This becomes very important in areas where resources are limited."

Initial results from canine tests look very promising. He hopes the vaccine will be available for animals in three to five years. Human vaccines will take longer.

"We are doing various things using the platform technology," He said. "What we are really good at is re-engineering them to make them do the things we like them to do. So, we are looking at different kinds of pathogens to develop into form, and so far we have been very fortunate that many of them worked really well. Some of them worked better than I would have imagined."

He's lab also is working on vaccines for HIV, tuberculosis and malaria using this technology.

"That is the fun part of science: You come up ideas, and of course it takes a long time to push it through, and sometimes what you thought would work doesn't, but sometimes it works out really well, and that is really exciting and fun," He said.

More information: Fu, Z. et al. jvi.asm.org/content/early/2012… c1-b86b-dafd8af65f51

add to favorites email to friend print save as pdf

Related Stories

Single vaccines to protect against both rabies and Ebola

Aug 25, 2011

Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protest against both rabies and ...

New rabies vaccine may require only a single shot... not six

Sep 18, 2009

A person, usually a child, dies of rabies every 20 minutes. However, only one inoculation may be all it takes for rabies vaccination, according to new research published in the Journal of Infectious Diseases by researchers at the ...

Recommended for you

Ebola reveals shortcomings of African solidarity

9 hours ago

As Africa's leaders meet in Ethiopia to discuss the Ebola crisis, expectations of firm action will be tempered by criticism over the continent's poor record in the early stages of the epidemic.

Second bird flu case confirmed in Canada

Jan 30, 2015

The husband of a Canadian who was diagnosed earlier this week with bird flu after returning from a trip to China has also tested positive for the virus, health officials said Friday.

What exactly is coronavirus?

Jan 30, 2015

The conflicts in Syria and Iraq are straining public health systems and public health efforts meant to prevent and detect the spread of infectious diseases. This is generating a "perfect storm" of conditions for outbreaks. Among the infections raising concern is Middle East Respiratory Syndrome, caused by a type of coronavirus, which emerged in 2012. ...

Scientists find Ebola virus is mutating

Jan 30, 2015

(Medical Xpress)—Researchers working at Institut Pasteur in France have found that the Ebola virus is mutating "a lot" causing concern in the African countries where the virus has killed over eight thous ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.